Your browser doesn't support javascript.
loading
HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression.
Kammers, Kai; Chen, Athena; Monaco, Daniel R; Hudelson, Sarah E; Grant-McAuley, Wendy; Moore, Richard D; Alter, Galit; Deeks, Steven G; Morrison, Charles S; Eller, Leigh A; Blankson, Joel N; Laeyendecker, Oliver; Ruczinski, Ingo; Eshleman, Susan H; Larman, H Benjamin.
Afiliação
  • Kammers K; Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Chen A; Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States.
  • Monaco DR; Department of Pathology and the Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Hudelson SE; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Grant-McAuley W; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Moore RD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Alter G; Department of Medicine, Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
  • Deeks SG; Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA, United States.
  • Morrison CS; Behavioral, Epidemiologic and Clinical Sciences, Family Health International (FHI) 360, Durham, NC, United States.
  • Eller LA; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
  • Blankson JN; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States.
  • Laeyendecker O; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Ruczinski I; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Eshleman SH; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD, United States.
  • Larman HB; Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States.
Front Immunol ; 12: 740395, 2021.
Article em En | MEDLINE | ID: mdl-34512672
ABSTRACT

Introduction:

Low HIV viral load is associated with delayed disease progression and reduced HIV transmission. HIV controllers suppress viral load to low levels in the absence of antiretroviral treatment (ART). We used an antibody profiling system, VirScan, to compare antibody reactivity and specificity in HIV controllers, non-controllers with treatment-induced viral suppression, and viremic non-controllers.

Methods:

The VirScan library contains 3,384 phage-displayed peptides spanning the HIV proteome. Antibody reactivity to these peptides was measured in plasma from a Discovery Cohort that included 13 elite controllers, 27 viremic controllers, 12 viremic non-controllers, and 21 non-controllers who were virally suppressed on ART. Antibody reactivity to selected peptides was also assessed in an independent cohort of 29 elite controllers and 37 non-controllers who were virally suppressed on ART (Validation Cohort) and in a longitudinal cohort of non-controllers.

Results:

In the Discovery Cohort, 62 peptides were preferentially targeted in HIV controllers compared to non-controllers who were virally suppressed on ART. These specificities were not significantly different when comparing controllers versus viremic non-controllers. Aggregate reactivity to these peptides was also high in elite controllers from the independent Validation Cohort. The 62 peptides formed seven clusters of homologous epitopes in env, gag, integrase, and vpu. Reactivity to one of these clusters located in gag p17 was inversely correlated with viral load set point in an independent cohort of non-controllers.

Conclusions:

Antibody reactivity was low in non-controllers suppressed on ART, but remained high in viremic controllers despite viral suppression. Antibodies in controllers and viremic non-controllers were directed against epitopes in diverse HIV proteins; higher reactivity against p17 peptides was associated with lower viral load set point. Further studies are needed to determine if these antibodies play a role in regulation of HIV viral load.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Paciente HIV Positivo não Progressor Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Paciente HIV Positivo não Progressor Idioma: En Ano de publicação: 2021 Tipo de documento: Article